Conventional gene augmentation therapies have shown great promise in clinical trials for treating recessive diseases, such as inherited retinal degenerations (IRDs) and hemophilia 1, 2 .
However, its application to dominant diseases is limited due to the requirement for silencing or ablating the gain-of-function or dominant-negative mutant alleles. While alternative RNAbased suppression-replacement approaches have also been actively pursued, the allelic specificity, longevity of the therapy, and regulation of gene expression levels have posed significant challenges for their broad application 3 . CRISPR/Cas9 gene editing technologies present an alternative approach to treat dominant diseases by addressing these challenges.
The CRISPR/Cas9 system has been revolutionary for genome editing because the Cas9 nuclease can be programmed to generate double-strand DNA breaks at specified genomic sites using a single guide RNA (sgRNA), which dictates much of the target site specificity 4 . The Cas9/sgRNA complex scans the genome for the presence of a protospacer adjacent motif (PAM), the critical first step of DNA target site recognition 4 . Recent studies in mice have shown that, when the disease-causing allele harbors unique PAM sequences that are not present in its wild-type counterpart, allele-specific genome editing by selectively targeting and permanently inactivating the mutant allele could be achieved while leaving the wild-type allele functionally intact [5] [6] [7] . However, many dominant alleles do not carry sequences that overlap with a target site PAM, making them refractory to this type of allele-specific editing strategy. One potential approach to expand the applicability of allele-specific genome editing is to develop strategies in which the disease-causing allele can be discriminated from the wild-type allele when the sequence differences are instead positioned within the spacer region of the Cas9/sgRNA target site. Streptococcus pyogenes Cas9 (SpCas9) is known to be generally ineffective at distinguishing between single nucleotide mismatches in much of its spacer sequence [8] [9] [10] , however, recent studies in human iPSCs and rat embryos have provided some encouraging evidence for the use of mismatches in the spacer sequence to achieve allele-specific genome editing [11] [12] [13] , suggesting that this strategy might work in a site-dependent manner. Furthermore, recently developed improvements in SpCas9 specificity may be leveraged to improve targeting specificity 14, 15 . In the present study, we investigated the feasibility of using this spacermediated allele-specific editing to ablate a dominant allele in a Rhodopsin-P23H knockin mice. This mouse model genetically and phenotypically recapitulates rhodopsin-associated autosomal dominant retinitis pigmentosa (adRP) 16 , the most common form of inherited retinal disease 17 .
Because the endogenous sequence surrounding the Rhodopsin-P23H mutation does not harbor any canonical NGG PAM sites for wild-type SpCas9, we designed two sgRNAs (sgRNA1 and sgRNA2) against sites with non-canonical NNCAGT and NGA PAMs that are accessible for engineered SaCas9-KKH and SpCas9-VQR nucleases, respectively 18, 19 (Fig. 1a) . The position of P23H mutation is 12bp upstream of the PAM in sgRNA1 and 4bp in sgRNA2. Plasmids encoding the sgRNA and its corresponding Cas9 nuclease were co-delivered via subretinal injection to neonatal mice (P0-P2), followed by in vivo electroporation. Assessment of the targeting fficiency and allele-specificity by targeted deep sequencing revealed robust disruption efficiency, but neither nuclease was able to distinguish the mutant P23H allele from the wildtype Rho allele, even though both preferentially targeted the mutant allele in heterozygous mice (Fig. 1b, 1c) . We therefore examined whether truncated sgRNAs bearing shortened 5' ends, which showed increased specificity of SpCas9 in a previous study 20 , could improve allele discrimination. A 17-nucleotide version of sgRNA2 (tru-sgRNA2) was designed and tested. When paired with tru-sgRNA2, SpCas9-VQR exclusively edited the P23H mutant allele with a cleavage efficiency of 28% in the homozygous mutant retinas, and no detectable cleavage in the wildtype controls (Fig. 1d) . To potentially further improve the on-target editing efficiency, trusgRNA2 was paired with SpCas9-VRQR (an improved version of SpCas9-VQR that has enhanced activity; Kleinstiver and Joung, unpublished data) and tested (Fig. 1e) . The on-target editing frequency induced by SpCas9-VRQR (44.8 ± 4.8%) for the P23H allele was significantly higher relative to SpCas9-VQR (22.1 ± 8.1%, p<0.001) in homozygous mice, with a low level of nuclease-induced editing of the wild-type allele (1.3 ± 0.3%) in the wild-type mice. As detailed below, this concomitant targeting of the wild-type allele did not abrogate the observed therapeutic benefit. Off-target cleavage of SpCas9-VRQR/tru-sgRNA2 at other closely matched sites was predicted by CCTop-CRISPR/Cas9 predictor 21 . Evaluation of the top 10 sites by PCR and deep sequencing showed that no indel was detected at 9 sites; while 3.12 ± 2.28% (n=3) of indels was detected at the site in Gm27760, which has 1bp mismatch from on-target site sequence ( Supplementary Fig. 1 
and Supplementary Table 1, 2).
To assess the potential therapeutic effectiveness of P23H targeting with SpCas9-VRQR and trusgRNA2, we analyzed the insertion or deletion mutation (indel) profiles of edited alleles across 10 independent experimental replicates and observed that 89.5 ± 3.3% of indels created frame shifts (Fig. 1f, 1g, Supplementary Fig 2) . Moreover, consistent with a previous report 22 , the indel pattern is nonrandom; the top two most frequent indels observed across different replicates accounts for 50.2 ± 4.7% of all indels (Fig. 1h, 1i ). Since the P23H mutation is located in the first exon of RHO, frame-shift indels are expected to create null alleles.
To confirm that allele-specific editing leads to altered expression of the mutant allele, we performed RT-PCR followed by targeted deep sequencing to determine the relative mRNA levels of wild-type, P23H and edited alleles in P14 heterozygous retinas. While approximately 22.8% edited alleles were detected at DNA level in the treated retinas (Fig. 2a) , only 4.8% mRNA from edited alleles were detected, with the majority of them being in-frame (Fig. 2b) . The ratio of wild-type mRNA (75.5 ± 2.3%) vs mutant P23H and edited mRNA (26.5 ± 2.3%) was significantly increased in the treated cells (2.8 ± 0.35) compared to that in the control cells (1.37±0.05) (Fig. 2b, 2c) . When the mRNA level was normalized to the wild-type allele, the ratio of wt vs. mutant mRNA was 1: 0.35 in the treated cells compared to 1: 0.73 in the untreated cell (Fig. 2d) , suggesting 38% decrease of mutant mRNA level in the treated cells. This result indicates that 38% of transfected cells express only wild-type rhodopsin, while the transcripts from edited mutant alleles have undergone nonsense mediated decay (Fig. 2e) ; this is consistent with the finding at the DNA level, where the majority of edited alleles harbor an outof-frame indel.
To gauge whether ablation of the P23H allele in the treated cells could lead to prevention or delay of photoreceptor degeneration in the regions of retina transfected with SpCas9-VRQR/ tru-sgRNA2 plasmids, we analyzed retinal structure in heterozygous Rho-P23H mice 5 weeks post-injection. The photoreceptor outer nuclear layer (ONL) was significantly thicker (p<0.05) in the treated EGFP positive region (41.13 ± 4.46 µm) than the adjacent untreated EGFP negative area (23.98 ± 2.39 µm) (Fig. 2f) . While five to six rows of photoreceptor cells remained in the treated area, only three to four rows were left in the untreated area (Fig. 2g) . Consistent with this finding, immunofluorescence analysis showed that the rhodopsin protein was localized correctly in the outer segments of the transfected photoreceptor cells, consistent with the ablation of the P23H mutant RNA, while in contrast the mutant Rho-P23H protein was mislocalized to the inner segments and cell bodies of the untreated cells (Fig. 2g) .
This study demonstrates for the first time that a spacer-mediated allele-specific genome editing approach is feasible to selectively inactivate a missense dominant allele at its native locus. This was accomplished by using a tru-sgRNA along with an alternative SpCas9 variant designed to target an alternative PAM sequence. Using this strategy, we observed a significant decrease of the mutant transcript and protein, which in turn led to preservation of photoreceptor morphology and viability in a mouse model of dominant RP. Similar phenotypic rescue was observed in two previous studies in transgenic mice in which CRISPR/Cas9 ablated the mutant rhodopsin transgene by targeting the sequences that differed between the species and host 23, 24 . With the continuing expansion of the CRISPR/Cas nuclease toolbox, many more human dominant alleles may become targetable using a similar allele-specific editing approach. Extending the allele-specific editing beyond discrimination at only the PAM significantly broadens the application of genome editing technologies and could lead to greater number of therapeutics for various dominant genetic diseases. Additional investigations are warranted for advancing this allele-specific approach towards clinical translation, including comprehensive evaluation of off-target activities, the development of more effective in vivo delivery, and the valuation of long-term therapeutic benefits and safety. Plasmid constructs. Plasmids encoding pCAG-SpCas9-VQR-P2A-EGFP, pCAG-SpCas9-VRQR-P2A-EGFP, and pCAG-KKH-SaCas9-P2A-EGFP sequences were generated via isothermal assembly. To generate sgRNA plasmids, oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, Iowa, USA), annealed, and ligated into BsmBI digested BPK2660 (Addgene #70709) or BPK1520 (Addgene #65777) for SaCas9 and SpCas9 sgRNAs, respectively.
Subretinal injection. P0-P2 pups were anesthetized by hypothermia and subretinally injected using standard method 25 . Briefly, 0.5µl of DNA solution containing Cas9-encoding plasmid with or without the sgRNA bearing plasmid (absolute amount of DNA is 0.6 µg for Cas9 and 0.3µg for sgRNA, respectively) was injected into the subretinal space using a 34G Hamilton syringe, followed by in vivo electroporation using five 90V square pulses of 50 milliseconds duration with a Electro Square Porator (BTX, Holliston, MA).
Retina dissociation and cell sorting. Eye were enucleated and stored in BGJB medium (Thermo Fisher Scientific, Waltham, MA) on ice. Retinas were isolated under a fluorescent dissection microscope to record the transfected region. 3-8 retinas were pooled and dissociated into single cells by incubation in solution A containing 1mg/ml pronase (Sigma-Aldrich, St. Louis, MO) and 2mM EGTA in BGJB medium at 37°C for 20 minutes. Solution A was gently removed from the vial, followed by adding equal amount of solution B containing 100 U/ml DNase I (New England Biolabs, Cambridge, MA ), 0.5% BSA, 2mM EGTA in BGJB medium. Cells were spin down at 700rpm for 3 min, supernatant was removed and cells were re-suspended in 1 X phosphate-buffered saline (PBS), filtered through the Cell Strainer (BD Biosciences, San Jose, CA), and submitted for sorting. EGFP positive and negative cells were collected by Cytomation MoFlo Cell Sorter (Cytomation, Fort Collins, CO).
Genomic DNA extraction and PCR. Genomic DNAs extraction from sorted cells was performed using DNA Extraction solution (Epicenter, Madison, WI) following the manufacturer's instructions. PCR using Taq-Pro Red Complete (Denville Scientific, Holliston, MA) and 100ng of genomic DNAs as template was performed to to amplify the sequence flanking the on-targeting and top 10 predicted off-targeting sequences for tru-sgRNA2 (Supplementary table 1, 2) . PCR thermocycling was conducted at 94°C for 4 minutes, followed by 35 cycles at 94°C for 30 seconds, 58°C for the P23H on-target primers or 59.4°C for the off-target sites, respectively, for 30 seconds, and 72°C for 30 seconds, followed by a terminal elongation step at 72°C for 10 minutes.
RNA extraction, RT-PCR. Total RNA from sorted EGFP positive and negative cells was extracted using the RNeasy Micro Kit (Qiagen, Hilden, Germany). Total RNA was reverse transcribed with the SuperScript IV First-Strand Synthesis System using Oligo(dT) 20 primer (Thermo Fisher Scientific, Rockford, IL). cDNA was used for PCR amplification with P23H primers using the condition described above and subjected for NGS analysis.
Targeted deep sequencing. PCR amplicons were analyzed by NGS performed by CCIB DNA core Facility at Massachusetts General Hospital (Cambridge, MA). Partial Illumina adaptor sequences and unique identifiers (barcodes) were attached by ligation to the 5′ and 3′ ends of the PCR amplicons. A subsequent low-cycle PCR amplification step completed the addition of full-length adaptor sequences. Paired-end sequencing of the resulting TruSeq-compatible paired-end Illumina libraries was performed on the Illumina MiSeq platform, utilizing V2 chemistry. Sequencing data was analyzed using CRISPResso program following by customized algorithm to correct nonsense single nucleotide polymorphisms (SNPs) due to NGS errors and consolidate indel counts 26 .
Immunostaining and microscope imaging. Mice were perfused with 4% para-formaldehyde (PFA) in PBS and eyes were marked for orientation using a small vessel cauterizer (Fine Scientific Tools, Foster City, CA) and enucleated. Eyes were post-fixed in 4% PFA for 2-3 hours, transferred into 30% sucrose in PBS at 4°C for overnight. Eye cups were embedded into OCT and 10µM sections were cut using Cryostat (Leica Microsystems). Cryosections were stained with 1: 1000 mouse anti-rhodopsin antibody (MAB5356, EMD Millipore, Billerica, MA), incubated at 4°C for overnight, followed by staining with goat anti mouse Alexa Fluor 555 secondary antibody (A-21422, Thermo Fisher, Waltham, MA) at 1: 1000 dilution for 1 hour at room temperature, and counterstained with Hoechst (62249, Thermo Fisher Scientific) at room temperature for 10 minutes, and mounted with Fluoromout G (Electron Microscopy Sciences, Hatfield, PA). Images were taken using the Eclipse Ti microscope.
Statistical analysis
All data was presented as mean ± s.e.m. Two-tailed unpaired t-test was used for data analysis. Statistical significance was considered when P value is < 0.05, 0.01 or 0.001. , and nuclei were counterstained with Hoechst (blue). RPE: retinal pigment epithelium, ONL: outer nuclear layer, INL: inner nuclear layer. GCL: ganglion cell layer. **** P < 0.0001, *** P < 0.001, * P < 0.05.
Supplementary materials
Supplementary Figure 1 . Evaluation of SpCas9-VRQR specificity when paired with tru-sgRNAs in vivo. Off-target editing frequency in P23H het mice was examined at the top 10 off-target sites. Samples were collected and analyzed 7 days post injection. Off-target data is represented as mean ± s.e.m(n=3), NGS of the PCR amplicon of the P23H site is used as positive control and that from the un-injected cells as a negative control.
Supplementary Figure 2 . indel profiles from 10 separate experiments. Total percentage of edited alleles carrying in-frame (red) or out-of-frame (blue) indels in P23H het mice injected with SpCas9-VRQR and tru-sgRNA2, data was analyzed 7 days post-injection.
